Research programme: nitric oxide-donating compounds - Ferrer/NicOx

Drug Profile

Research programme: nitric oxide-donating compounds - Ferrer/NicOx

Alternative Names: GF-015646-00; GF-015647; NCX 1047

Latest Information Update: 12 Aug 2013

Price : $50

At a glance

  • Originator NicOx
  • Developer Ferrer; NicOx
  • Class Corticosteroids
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dermatitis; Psoriasis

Most Recent Events

  • 30 Apr 2013 NiCox & Ferrer terminate their collaboration agreement for nitric oxide-donating steroid compounds for dermatology indications
  • 30 Apr 2013 Discontinued - Preclinical for Dermatitis in Spain (Topical)
  • 30 Apr 2013 Discontinued - Preclinical for Psoriasis in Spain (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top